The intracellular life of Cryptococcus neoformans

Annual Review of Pathology: Mechanisms of Disease

Volumn 9, Issue , 2014, Pages 219-238

  Coelho, Carolina ^a,b   Bocca, Anamelia L ^c   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

C. neoformans killing; Disease tolerance; Fungal immunity; Granuloma; Intracellular pathogen; Trojan horse

Indexed keywords

ANIMAL; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DISEASE MODEL; EXOCYTOSIS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; LIFE CYCLE STAGE; MACROPHAGE; MICROBIOLOGY; PATHOGENICITY; PHAGOCYTE; PHYSIOLOGY; REVIEW; VIRULENCE;

ANIMALS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DISEASE MODELS, ANIMAL; EXOCYTOSIS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOCOMPROMISED HOST; LIFE CYCLE STAGES; MACROPHAGES; PHAGOCYTES; VIRULENCE;

EID: 84897020113     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-012513-104653     Document Type: Article

References (133)

1. Barnett JA. 2010. A history of research on yeasts 14: medical yeasts part 2, Cryptococcus neoformans. Yeast 27(11):875-904
2. Lin X, Heitman J. 2006. The biology of the Cryptococcus neoformans species complex. Annu. Rev. Microbiol. 60:69-105
3. LindellDM, BallingerMN, McDonald RA, Toews GB, Huffnagle GB. 2006. Immunologic homeostasis during infection: coexistence of strong pulmonary cell-mediated immunity to secondary Cryptococcus neoformans infection while the primary infection still persists at low levels in the lungs. J. Immunol. 177(7):4652-61
4. Goldman DL, Khine H, Abadi J, Lindenberg DJ, Pirofski L-A, et al. 2001. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 107(5):e66
5. Garcia-Hermoso D, Janbon G, Dromer F. 1999. Epidemiological evidence for dormant Cryptococcus neoformans infection. J. Clin. Microbiol. 37(10):3204-9
6. Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J. 2011. Harrisons Principles of Internal Medicine, Vols. 1, 2. New York: McGraw-Hill. 18th ed.
7. Chen LC, Goldman DL, Doering TL, PirofskiL-A, Casadevall A. 1999. Antibody response to Cryptococcus neoformans proteins in rodents and humans. Infect. Immun. 67(5):2218-24
8. Giles SS, Dagenais TRT, Botts MR, Keller NP, Hull CM. 2009. Elucidating the pathogenesis of spores from the human fungal pathogen Cryptococcus neoformans. Infect. Immun. 77(8):3491-500
9. Shibuya K, Hirata A, Omuta J, Sugamata M, Katori S, et al. 2005. Granuloma and cryptococcosis. J. Infect. Chemother. 11(3):115-22
10. Lindell DM, Ballinger MN, McDonald RA, Toews GB, Huffnagle GB. 2006. Diversity of the T-cell response to pulmonary Cryptococcus neoformans infection. Infect. Immun. 74(8):4538-48
11. HuffnagleGB, Yates JL, Lipscomb MF. 1991. Immunity to a pulmonary Cryptococcus neoformans infection requires both CD4+ and CD8+ T cells. J. Exp. Med. 173(4):793-800
12. Lim TS, Murphy JW. 1980. Transfer of immunity to cryptococcosis by T-enriched splenic lymphocytes from Cryptococcus neoformans-sensitized mice. Infect. Immun. 30(1):5-11
13. Zaragoza O, Alvarez M, Telzak A, Rivera J, Casadevall A. 2007. The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response. Infect. Immun. 75(6):2729-39
14. Rhodes JC. 1985. Contribution of complement component C5 to the pathogenesis of experimental murine cryptococcosis. Sabouraudia 23(3):225-34
15. Hoag KA, Lipscomb MF, Izzo AA, Street NE. 1997. IL-12 and IFN-γ are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice. Am. J. Respir. Cell Mol. Biol. 17(6):733-39
16. Chen G-H, McDonald RA, Wells JC, Huffnagle GB, Lukacs NW, Toews GB. 2005. The γinterferon receptor is required for the protective pulmonary inflammatory response to Cryptococcus neoformans. Infect. Immun. 73(3):1788-96
17. Decken K, Kohler G, Palmer-Lehmann K, Wunderlin A, Mattner F, et al. 1998. Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect. Immun. 66(10):4994-5000
18. Kobayashi M, Ito M, Sano K, Koyama M. 2001. Granulomatous and cytokine responses to pulmonary Cryptococcus neoformans in two strains of rats. Mycopathologia 151(3):121-30
19. Arora S, Olszewski MA, Tsang TM, McDonald RA, Toews GB, Huffnagle GB. 2011. Effect of cytokine interplay on macrophage polarization during chronic pulmonary infection with Cryptococcus neoformans. Infect. Immun. 79(5):1915-26
20. Jain AV, Zhang Y, Fields WB, McNamara DA, Choe MY, et al. 2009. Th2 but not Th1 immune bias results in altered lung functions in a murine model of pulmonary Cryptococcus neoformans infection. Infect. Immun. 77(12):5389-99
21. Zhang Y, Wang F, Tompkins KC, McNamara A, Jain AV, et al. 2009. Robust Th1 and Th17 immunity supports pulmonary clearance but cannot prevent systemic dissemination of highly virulent Cryptococcus neoformans H99. Am. J. Pathol. 175(6):2489-500
22. StenzelW, MullerU, KohlerG, Heppner FL, Blessing M, et al. 2009. IL-4/IL-13-dependent alternative activation ofmacrophages but notmicroglial cells is associated with uncontrolled cerebral cryptococcosis. Am. J. Pathol. 174(2):486-96
23. Kawakami K, Qifeng X, Tohyama M, Qureshi MH, Saito A. 1996. Contribution of tumour necrosis factor-Alpha (TNF-α) in host defence mechanism against Cryptococcus neoformans. Clin. Exp. Immunol. 106(3):468-74
24. Conti HR, Gaffen SL. 2010. Host responses to Candida albicans: Th17 cells and mucosal candidiasis. Microbes Infect. 12(7):518-27
25. Wozniak KL, Young ML, Wormley FL. 2011. Protective immunity against experimental pulmonary cryptococcosis in T cell-depleted mice. Clin. Vaccine Immunol. 18(5):717-23
26. Monga DP. 1981. Role of macrophages in resistance of mice to experimental cryptococcosis. Infect. Immun. 32(3):975-78
27. Osterholzer JJ, Milam JE, Chen G-H, Toews GB, Huffnagle GB, Olszewski MA. 2009. Role of dendritic cells and alveolar macrophages in regulating early host defense against pulmonary infection with Cryptococcus neoformans. Infect. Immun. 77(9):3749-58
28. Shao X, Mednick A, Alvarez M, van Rooijen N, Casadevall A, Goldman DL. 2005. An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J. Immunol. 175(5):3244-51
29. Feldmesser M, Casadevall A, Kress Y, Spira G, Orlofsky A. 1997. Eosinophil-Cryptococcus neoformans interactions in vivo and in vitro. Infect. Immun. 65(5):1899-907
30. Mednick AJ, Feldmesser M, Rivera J, Casadevall A. 2003. Neutropenia alters lung cytokine production in mice and reduces their susceptibility to pulmonary cryptococcosis. Eur. J. Immunol. 33(6):1744-53
31. PiehlerD, Stenzel W, Grahnert A, Held J, Richter L, et al. 2011. Eosinophils contribute to IL-4 production and shape the T-helper cytokine profile and inflammatory response in pulmonary cryptococcosis. Am. J. Pathol. 179(2):733-44
32. Garro AP, Chiapello LS, Baronetti JL, Masih DT. 2010. Rat eosinophils stimulate the expansion of Cryptococcus neoformans-specificCD4+ andCD8+ Tcells with aT-helper 1 profile. Immunology 132(2):174-87
33. Casadevall A. 2012. Amoeba provide insight into the origin of virulence in pathogenic fungi. Adv. Exp. Med. Biol. 710:1-10
34. Mansour MK, Yauch LE, Rottman JB, Levitz SM. 2004. Protective efficacy of antigenic fractions in mouse models of cryptococcosis. Infect. Immun. 72(3):1746-54
35. Kawakami K. 2004. Regulation by innate immune T lymphocytes in the host defense against pulmonary infection with Cryptococcus neoformans. Jpn. J. Infect. Dis. 57(4):137-45
36. Hardison SE, Wozniak KL, Kolls JK, Wormley FL. 2010. Interleukin-17 is not required for classical macrophage activation in a pulmonary mouse model of Cryptococcus neoformans infection. Infect. Immun. 78(12):5341-51
37. Hardison SE, Herrera G, YoungML, Hole CR, Wozniak KL, Wormley FL. 2012. Protective immunity against pulmonary cryptococcosis is associated with STAT1-mediated classical macrophage activation. J. Immunol. 189(8):4060-68
38. Hardison SE, Ravi S, Wozniak KL, YoungML, OlszewskiMA, Wormley FL. 2010. Pulmonary infection with an interferon-γ-producing Cryptococcus neoformans strain results in classical macrophage activation and protection. Am. J. Pathol. 176(2):774-85
39. Baker RD, Haugen RK. 1955. Tissue changes and tissue diagnosis in cryptococcosis; a study of 26 cases. Am. J. Clin. Pathol. 25(1):14-24
40. Schwartz DA. 1988. Characterization of the biological activity of Cryptococcus infections in surgical pathology. The Budding Index and Carminophilic Index. Ann. Clin. Lab. Sci. 18(5):388-97
41. Shibuya K, Coulson WE, Wollman JS, Wakayama M, Ando T, et al. 2001. Histopathology of cryptococcosis and other fungal infections in patients with acquired immunodeficiency syndrome. Int. J. Infect. Dis. 5(2):78-85
42. Goldman DL, Lee SC, Mednick AJ, Montella L, Casadevall A. 2000. Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness to cryptococcal polysaccharide. Infect. Immun. 68(2):832-38
43. Feldmesser M, Kress Y, Novikoff P, Casadevall A. 2000. Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect. Immun. 68(7):4225-37
44. Nessa K, Gross NT, Jarstrand C, Johansson A, Camner P. 1997. In vivo interaction between alveolar macrophages and Cryptococcus neoformans. Mycopathologia 139(1):1-7
45. Goldman D, Lee SC, Casadevall A. 1994. Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect. Immun. 62(11):4755-61
46. CharlierC, Nielsen K, Daou S, Brigitte M, Chretien F, Dromer F. 2009. Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect. Immun. 77(1):120-27
47. Kechichian TB, Shea J, Del PoetaM. 2007. Depletion of alveolar macrophages decreases the dissemination of a glucosylceramide-deficient mutant of Cryptococcus neoformans in immunodeficient mice. Infect. Immun. 75(10):4792-98
48. Cross CE, Bancroft GJ. 1995. Ingestion of acapsular Cryptococcus neoformans occurs via mannose and β-glucan receptors, resulting in cytokine production and increased phagocytosis of the encapsulated form. Infect. Immun. 63(7):2604-11
49. Giles SS, Zaas AK, Reidy MF, Perfect JR, Wright JR. 2007. Cryptococcus neoformans is resistant to surfactant protein A mediated host defense mechanisms. PLoS ONE 2(12):e1370
50. Taborda CP, Casadevall A. 2002. CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity 16(6):791-802
51. Bocca AL, Coelho C, Casadevall A. 2012. Dectin-1 pathway activation is important to Cryptococcus neoformans killing. J. Immunol. 188(Meet. Abstr. Suppl.):67.10. http://www.jimmunol.org/cgi/content/meeting
52. Shapiro S, Beenhouwer DO, Feldmesser M, Taborda C, Carroll MC, et al. 2002. Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3. Infect. Immun. 70(5):2598-604
53. Means TK, Mylonakis E, Tampakakis E, Colvin RA, Seung E, et al. 2009. Evolutionarily conserved recognition and innate immunity to fungal pathogens by the scavenger receptors SCARF1 and CD36. J. Exp. Med. 206(3):637-53
54. Heinsbroek SEM, Taylor PR, Martinez FO, Martinez-Pomares L, Brown GD, Gordon S. 2008. Stagespecific sampling by pattern recognition receptors during Candida albicans phagocytosis. PLoS Pathog. 4(11):e1000218
55. Faro-Trindade I, Willment JA, Kerrigan AM, Redelinghuys P, Hadebe S, et al. 2012. Characterisation of innate fungal recognition in the lung. PLoS ONE 7(4):e35675
56. Nakamura K, Kinjo T, Saijo S, Miyazato A, Adachi Y, et al. 2007. Dectin-1 is not required for the host defense to Cryptococcus neoformans. Microbiol. Immunol. 51(11):1115-19
57. Marakalala MJ, Vautier S, Potrykus J, Walker LA, Shepardson KM, et al. 2013. Differential adaptation of Candida albicans in vivo modulates immune recognition by Dectin-1. PLoS Pathog. 9(4):e1003315
58. Biondo C, Midiri A, Messina L, Tomasello F, Garufi G, et al. 2005. MyD88 and TLR2, but not TLR4, are required for host defense against Cryptococcus neoformans. Eur. J. Immunol. 35(3):870-78
59. Dan JM, Kelly RM, Lee CK, Levitz SM. 2008. Role of the mannose receptor in a murine model of Cryptococcus neoformans infection. Infect. Immun. 76(6):2362-67
60. Nakamura K, Miyazato A, Xiao G, Hatta M, Inden K, et al. 2008. Deoxynucleic acids from Cryptococcus neoformans activate myeloid dendritic cells via a TLR9-dependent pathway. J. Immunol. 180(6):4067-74
61. Wang JP, Lee CK, Akalin A, Finberg RW, Levitz SM. 2011. Contributions of the MyD88-dependent receptors IL-18R, IL-1R, and TLR9 to host defenses following pulmonary challenge with Cryptococcus neoformans. PLoS ONE 6(10):e26232
62. Guillot L, Carroll SF, BadawyM, Qureshi ST. 2008. Cryptococcus neoformans induces IL-8 secretion and CXCL1 expression by human bronchial epithelial cells. Respir. Res. 9(1):9
63. Ganendren R, Carter E, Sorrell T, Widmer F, Wright L. 2006. Phospholipase B activity enhances adhesion of Cryptococcus neoformans to a human lung epithelial cell line. Microbes Infect. 8(4):1006-15
64. Sabiiti W, May RC. 2012. Capsule independent uptake of the fungal pathogen Cryptococcus neoformans into brain microvascular endothelial cells. PLoS ONE 7(4):e35455
65. Qin Q-M, Luo J, Lin X, Pei J, Li L, et al. 2011. Functional analysis of host factors that mediate the intracellular lifestyle of Cryptococcus neoformans. PLoS Pathog. 7(6):e1002078
66. Artavanis-Tsakonas K, Love JC, Ploegh HL, Vyas JM. 2006. Recruitment of CD63 to Cryptococcus neoformans phagosomes requires acidification. Proc. Natl. Acad. Sci. USA 103(43):15945-50
67. Levitz SM, Harrison TS, Tabuni A, Liu X. 1997. Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation. J. Clin. Investig. 100(6):1640-46
68. Wozniak KL, Levitz SM. 2008. Cryptococcus neoformans enters the endolysosomal pathway of dendritic cells and is killed by lysosomal components. Infect. Immun. 76(10):4764-71
69. Nicola AM, Albuquerque P, Martinez LR, Dal-Rosso RA, Saylor C, et al. 2012. Macrophage autophagy in immunity to Cryptococcus neoformans and Candida albicans. Infect. Immun. 80(9):3065-76
70. Tucker SC, Casadevall A. 2002. Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc. Natl. Acad. Sci. USA 99(5):3165-70
71. Gross NT, Hultenby K, Mengarelli S, Camner P, Jarstrand C. 2000. Lipid peroxidation by alveolar macrophages challenged with Cryptococcus neoformans, Candida albicans or Aspergillus fumigatus. Med. Mycol. 38(6):443-49
72. Ben-Abdallah M, Sturny-Leclere A, Ave P, Louise A, Moyrand F, et al. 2012. Fungal-induced cell cycle impairment, chromosome instability and apoptosis via differential activation of NF-κB. PLoS Pathog. 8(3):e1002555
73. Villena SN, Pinheiro RO, Pinheiro CS, Nunes MP, Takiya CM, et al. 2008. Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand. Cell. Microbiol. 10(6):1274-85
74. Luo Y, Tucker SC, Casadevall A. 2005. Fc- and complement-receptor activation stimulates cell cycle progression of macrophage cells from G1 to S. J. Immunol. 174(11):7226-33
75. Luo Y, Casadevall A. 2010. Intracellular cryptococci suppress Fc-mediated cyclin D1 elevation. Commun. Integr. Biol. 3(4):390-91
76. Coelho C, Tesfa L, Zhang J, Rivera J, Goncalves T, Casadevall A. 2012. Analysis of cell cycle and replication of mouse macrophages after in vivo and in vitro Cryptococcus neoformans infection using laser scanning cytometry. Infect. Immun. 80(4):1467-78
77. Thi EP, Lambertz U, Reiner NE. 2012. Sleeping with the enemy: how intracellular pathogens cope with a macrophage lifestyle. PLoS Pathog. 8(3):e1002551
78. Levitz SM, Farrell TP. 1990. Growth inhibition of Cryptococcus neoformans by cultured humanmonocytes: role of the capsule, opsonins, the culture surface, and cytokines. Infect. Immun. 58(5):1201-9
79. Shoham S, Levitz SM. 2005. The immune response to fungal infections. Br. J. Haematol. 129(5):569-82
80. DerengowskiLS, Paes HC, Albuquerque P, Tavares AHFP, Fernandes L, et al. 2013. The transcriptional response of Cryptococcus neoformans to ingestion by Acanthamoeba castellanii and macrophages provides insights into the evolutionary adaptation into the mammalian host. Eukaryot. Cell 12(5):761-74
81. Fan W, Kraus PR, Boily M-J, Heitman J. 2005. Cryptococcus neoformans gene expression during murine macrophage infection. Eukaryot. Cell 4(8):1420-33
82. Snelgrove RJ, Edwards L, Williams AE, Rae AJ, Hussell T. 2006. In the absence of reactive oxygen species, T cells default to a Th1 phenotype and mediate protection against pulmonary Cryptococcus neoformans infection. J. Immunol. 177(8):5509-16
83. Alspaugh JA, Granger DL. 1991. Inhibition of Cryptococcus neoformans replication by nitrogen oxides supports the role of these molecules as effectors of macrophage-mediated cytostasis. Infect. Immun. 59(7):2291-96
84. Goldman D, Cho Y, Zhao M, Casadevall A, Lee SC. 1996. Expression of inducible nitric oxide synthase in rat pulmonary Cryptococcus neoformans granulomas. Am. J. Pathol. 148(4):1275-82
85. Rivera J, Mukherjee J, WeissLM, Casadevall A. 2002. Antibody efficacy in murine pulmonary Cryptococcus neoformans infection: a role for nitric oxide. J. Immunol. 168(7):3419-27
86. Aguirre KM, Gibson GW. 2000. Differing requirement for inducible nitric oxide synthase activity in clearance of primary and secondary Cryptococcus neoformans infection. Med. Mycol. 38(5):343-53
87. de Jesus-Berrios M, Liu L, Nussbaum JC, Cox GM, Stamler JS, Heitman J. 2003. Enzymes that counteract nitrosative stress promote fungal virulence. Curr. Biol. 13(22):1963-68
88. Murphy JW, HidoreMR, Wong SC. 1993. Direct interactions of human lymphocytes with the yeast-like organism, Cryptococcus neoformans. J. Clin. Investig. 91(4):1553-66
89. Levitz SM, Dupont MP, Smail EH. 1994. Direct activity of human T lymphocytes and natural killer cells against Cryptococcus neoformans. Infect. Immun. 62(1):194-202
90. Kelly RM, Chen J, Yauch LE, Levitz SM. 2005. Opsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans. Infect. Immun. 73(1):592-98
91. Mambula SS, Simons ER, Hastey R, Selsted ME, Levitz SM. 2000. Human neutrophil-mediated nonoxidative antifungal activity against Cryptococcus neoformans. Infect. Immun. 68(11):6257-64
92. ArataniY. 2006. Contribution of the myeloperoxidase-dependent oxidative system to host defence against Cryptococcus neoformans. J. Med. Microbiol. 55(9):1291-99
93. Hole CR, Bui H, Wormley FL, Wozniak KL. 2012. Mechanisms of dendritic cell lysosomal killing of Cryptococcus. Sci. Rep. 2:739
94. Laskin DL, Sunil VR, Gardner CR, Laskin JD. 2011. Macrophages and tissue injury: agents of defense or destruction? Annu. Rev. Pharmacol. Toxicol. 51:267-88
95. Trost M, English L, Lemieux S, Courcelles M, Desjardins M, Thibault P. 2009. The phagosomal proteome in interferon-γ-Activated macrophages. Immunity 30(1):143-54
96. Bliska JB, Casadevall A. 2009. Intracellular pathogenic bacteria and fungi-A case of convergent evolution? Nat. Rev. Microbiol. 7:165-71
97. Zaragoza O, Garcia-Rodas R, Nosanchuk JD, Cuenca-Estrella M, Rodriguez-Tudela JL, Casadevall A. 2010. Fungal cell gigantism during mammalian infection. PLoS Pathog. 6(6):e1000945
98. Okagaki LH, Strain AK, Nielsen JN, Charlier C, Baltes NJ, et al. 2010. Cryptococcal cell morphology affects host cell interactions and pathogenicity. PLoS Pathog. 6(6):e1000953
99. Alvarez M, Burn T, Luo Y, Pirofski L-A, Casadevall A. 2009. The outcome of Cryptococcus neoformans intracellular pathogenesis in human monocytes. BMC Microbiol. 9:51
100. Alvarez M, Casadevall A. 2006. Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages. Curr. Biol. 16(21):2161-65
101. Ma H, Croudace JE, Lammas DA, May RC. 2006. Expulsion of live pathogenic yeast by macrophages. Curr. Biol. 16(21):2156-60
102. Nicola AM, Robertson EJ, Albuquerque P, Derengowski LDS, Casadevall A. 2011. Nonlytic exocytosis of Cryptococcus neoformans from macrophages occurs in vivo and is influenced by phagosomal pH. mBio 2(4):e00167-11
103. Johnston SA, MayRC. 2010. The human fungal pathogen Cryptococcus neoformans escapes macrophages by a phagosome emptying mechanism that is inhibited by Arp2/3 complex-mediated actin polymerisation. PLoS Pathog. 6(8):e1001041
104. Carnell M, Zech T, Calaminus SD, Ura S, Hagedorn M, et al. 2011. Actin polymerization driven by WASHcausesV-ATPase retrieval and vesicle neutralization before exocytosis. J. Cell Biol. 193(5):831-39
105. Maruvada R, Zhu L, Pearce D, Zheng Y, Perfect J, et al. 2012. Cryptococcus neoformans phospholipase B1 activates host cell Rac1 for traversal across the blood-brain barrier. Cell. Microbiol. 14(10):1544-53
106. Voelz K, Lammas DA, May RC. 2009. Cytokine signaling regulates the outcome of intracellular macrophage parasitism by Cryptococcus neoformans. Infect. Immun. 77(8):3450-57
107. Weiss G, Bogdan C, Hentze MW. 1997. Pathways for the regulation of macrophage iron metabolism by the anti-inflammatory cytokines IL-4 and IL-13. J. Immunol. 158(1):420-25
108. Kim W-K, Corey S, Alvarez X, Williams K. 2003. Monocyte/macrophage traffic in HIV and SIV encephalitis. J. Leukoc. Biol. 74(5):650-56
109. Chang YC, StinsMF, McCafferyMJ, MillerGF, Pare DR, et al. 2004. Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infect. Immun. 72(9):4985-95
110. He X, Lyons DM, Toffaletti DL, Wang F, Qiu Y, et al. 2012. Virulence factors identified by Cryptococcus neoformans mutant screen differentially modulate lung immune responses and brain dissemination. Am. J. Pathol. 181(4):1356-66
111. Rao PK, Singh CR, Jagannath C, Li Q. 2009. A systems biology approach to study the phagosomal proteome modulated by mycobacterial infections. Int. J. Clin. Exp. Med. 2(3):233-47
112. Cox GM, McDade HC, Chen SC, Tucker SC, GottfredssonM, et al. 2001. Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol. Microbiol. 39(1):166-75
113. Casadevall A, Pirofski L-A. 2003. The damage-response framework of microbial pathogenesis. Nat. Rev. Microbiol. 1(1):17-24
114. Medzhitov R, Schneider DS, Soares MP. 2012. Disease tolerance as a defense strategy. Science 335(6071):936-41
115. Alvarez-Rueda N, Albassier M, Allain S, Deknuydt F, Altare F, Le Pape P. 2012. First human model of in vitro Candida albicans persistence within granuloma for the reliable study of host-fungi interactions. PLoS ONE 7(6):e40185
116. Vignery A. 2008. Macrophage fusion: molecular mechanisms. Methods Mol. Biol. 475:149-61
117. Evans SE, TuvimMJ, FoxCJ, SachdevN, Gibiansky L, Dickey BF. 2011. Inhaled innate immune ligands to prevent pneumonia. Br. J. Pharmacol. 163(1):195-206
118. Bunting LA, Neilson JB, Bulmer GS. 1979. Cryptococcus neoformans: gastronomic delight of a soil ameba. Sabouraudia 17(3):225-32
119. Ruiz A, Neilson JB, Bulmer GS. 1982. Control of Cryptococcus neoformans in nature by biotic factors. Sabouraudia 20(1):21-29
120. Steenbergen JN, Casadevall A. 2003. The origin and maintenance of virulence for the human pathogenic fungus Cryptococcus neoformans. Microbes Infect. 5(7):667-75
121. Chrisman CJ, Alvarez M, Casadevall A. 2010. Phagocytosis of Cryptococcus neoformans by, and nonlytic exocytosis from, Acanthamoeba castellanii. Appl. Environ. Microbiol. 76(18):6056-62
122. ChrismanCJ, Albuquerque P, Guimaraes AJ, Nieves E, Casadevall A. 2011. Phospholipids trigger Cryptococcus neoformans capsular enlargement during interactions with amoebae and macrophages. PLoS Pathog. 7(5):e1002047
123. Nakamura K, Miyagi K, Koguchi Y, Kinjo Y, Uezu K, et al. 2006. Limited contribution of Toll-like receptor 2 and 4 to the host response to a fungal infectious pathogen, Cryptococcus neoformans. FEMS Immunol. Med. Microbiol. 47(1):148-54
124. MongaDP, Kumar R, Mohapatra LN. 1979. Experimental cryptococcosis in normal and B-cell-deficient mice. Infect. Immun. 23(1):1-3
125. Hill JO, Aguirre KM. 1994. CD4+ T cell-dependent acquired state of immunity that protects the brain against Cryptococcus neoformans. J. Immunol. 152(5):2344-50
126. Yuan RR, Casadevall A, Oh J, Scharff MD. 1997. T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc. Natl. Acad. Sci. USA 94(6):2483-88
127. Kawakami K, Koguchi Y, Qureshi MH, Kinjo Y, Yara S, et al. 2000. Reduced host resistance and Th1 response to Cryptococcus neoformans in interleukin-18 deficient mice. FEMS Microbiol. Lett. 186(1):121-26
128. Muller U, Stenzel W, Kohler G, Werner C, Polte T, et al. 2007. IL-13 induces disease-promoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans. J. Immunol. 179(8):5367-77
129. Kleinschek MA, MullerU, Brodie SJ, StenzelW, KohlerG, et al. 2006. IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12. J. Immunol. 176(2):1098-106
130. Gyetko MR, Chen G-H, McDonald RA, Goodman R, Huffnagle GB, et al. 1996. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model. J. Clin. Investig. 97(8):1818-26
131. Beenhouwer DO, Shapiro S, Feldmesser M, Casadevall A, Scharff MD. 2001. Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans. Infect. Immun. 69(10):6445-55
132. Williams AE, Humphreys IR, Cornere M, Edwards L, Rae A, Hussell T. 2005. TGF-β prevents eosinophilic lung disease but impairs pathogen clearance. Microbes Infect. 7(3):365-74
133. Casadevall A, Pirofski L-A. 2012. Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases. Cell Host Microbe 11(5):447-56